Piramal Enterprises saw its share price climb over 8% during Tuesday’s intraday trades, fueled by news of a significant financial boost from its divestment deal with Life Molecular Imaging. The stock opened at ₹960.05 on the BSE, slightly above Monday’s close of ₹950.35, and surged to an intraday high of ₹1,027.75. The rally was sparked by Piramal’s announcement that it expects to receive approximately $140 million as part of a deferred payment from the sale of its step-down subsidiary, Piramal Imaging SA, to Alliance Medical Acquisitionco Limited (AMAL). This agreement, originally inked in 2018, included a clause for deferred consideration tied to the future profits of Piramal Imaging SA and its subsidiaries. On Monday, January 13, 2025, Piramal disclosed that Life Healthcare Group Holdings Limited, which acquired Piramal Imaging SA as part of the earlier deal, has now signed binding agreements to sell Life Molecular Imaging Limited, a member of the Imaging Group. The transaction is pending shareholder and regulatory approvals but is expected to close in FY 2026. The anticipated $140 million payout represents the first tranche of earnings, with a potential to increase to a maximum of $200 million, contingent on future profits and eligible earnouts from the Imaging Group. This development signals a strategic financial gain for Piramal Enterprises, with investors cheering the prospect of a substantial cash inflow.